Dipenkumar Modi, MD, of the Karmanos Cancer Institute recently presented an interim analysis of the HCRN-LYM22-565 study at the European Hematology Association (EHA) 2025 Congress, held June 12–15 in Milan, Italy.
The phase II investigator-initiated study, led by Dr. Modi, evaluates the combination of epcoritamab, gemcitabine, dexamethasone, and cisplatin in patients with relapsed or refractory large B-cell lymphoma. Interim results suggest that the combination is clinically active with a manageable safety profile even in a heavily pre-treated population. The study is ongoing.
Abstract Summary:
- Title: Epcoritamab with gemcitabine, dexamethasone, and cisplatin (epco-gdp) in relapsed refractory large b-cell lymphoma – an interim analysis of phase II multicenter investigated-initiated trial
- Authors: Dipenkumar Modi, Vy Ong, Seongho Kim, Abhinav Deol, Emily Ayers, Varun Mittal
- See full abstract: https://congress-distribution.ehaweb.org/from.storage?image=RZshABASE-rg9u-zI63Z1Ne40j0OI90bNqBJ3cQ4A9xeY52T3TthSyoniFhf1Zwn0
Congratulations to Dr. Modi and all co-authors and teams participating in this clinical trial.
Learn more: https://hoosiercancer.org/all-clinical-trials/hcrn-lym22-565/
About Hoosier Cancer Research Network:
Hoosier Cancer Research Network conducts innovative cancer clinical trials in collaboration with more than 100 academic and community clinical research sites across the United States. Our studies are designed by cancer researchers from our member institutions. The HCRN staff includes 55 team members who work together to support all aspects of the studies we manage, from the time we receive the initial concept from a researcher through the final publication of the study results. Currently, we are supporting more than 70 clinical trials across a wide range of cancer types. Over our 40-year history, more than 10,000 participants have enrolled in our clinical trials, leading to important discoveries that help cancer patients live longer and better after their cancer diagnosis.
